GlobeNewswire

World’s First-and-Only Dante Extender for Pro-AV Systems Delivers Ethernet and Power over Existing Copper Wire

Share

By extending Ethernet up to 3,300 feet (1,000 meters) over common copper cable, the CopperLink™ CL1151E revolutionizes infrastructure requirements for Pro-AV systems that use Dante-enabled devices

CopperLink
Ethernet Extenders…  Going the Distance!

GAITHERSBURG, Md., April 29, 2019 (GLOBE NEWSWIRE) -- Patton—US manufacturer of copper and fiber network-connectivity solutions for Pro-AV systems—is about to release the world’s first-and-only Dante Extender:  the CopperLink™ CL1151E.

The revolutionary CL1151E Dante Extender delivers Power-over-Ethernet to Digital audio networking through Ethernet (Dante) devices while extending Ethernet segments up to 3,300 feet (1,000 meters) over existing copper twisted-pair cabling.

Patton’s CL1151E drastically reduces overall project costs by enabling audio-visual system designers, integrators, and installers to use already-installed copper wiring.

Patton gives customers the flexibility to place Dante-enabled devices exactly where they are wanted and needed by smashing the 100-meter distance limitation of standard Ethernet.

As the Internet of Things (IoT) expands globally, demand is surging in the audio-video space for IP/Ethernet-connected devices. Because it strikes the perfect balance of speed, cost, and ease of use, Power-over-Ethernet (PoE) is growing increasingly popular.

Now, with Patton’s Dante Extender, Pro-AV engineers can instantaneously install (Dante or non-Dante) PoE-capable devices—without the delay and costly overhead of installing new cabling infrastructure.

The CopperLink CL1151E kit from Patton enables Ethernet connectivity of DANTE-enabled devices over existing speaker, alarm, or even CCTV coaxial cabling. 

“We just made life a whole lot easier for the Pro-AV world,” said Johnnie Grant III, CopperLink Product Manager. “We offer instant AVoIP connectivity—without the distance limitations of Ethernet or requirements for power outlets.”

Dante, by Audinate, is the audio networking solution that has been adopted by the Pro-AV world with over 1,600 Dante-enabled products on the market. Now those devices can be more easily inter-connected without worrying about the length of the cable spans.

In related news, last week Patton announced the company has contributed to the rebuilding effort in the Middle East by delivering a secure IP-telephony communications solution for a national oil and gas ministry.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation29.5.2020 12:45:00 CESTPress release

Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast cancer patients whose tumors harbor a PIK3CA mutation in Europe Phase III trial showed Piqray plus fulvestrant nearly doubled median PFS (11.0 vs. 5.7 months) in this patient population, compared to fulvestrant alone PIK3CA mutations affect approximately 40% of HR+/HER2- advanced breast cancer patients and are linked to cancer growth and a poorer disease prognosis in the metastatic setting The digital press release with multimedia content can be accessed here: Basel, May 29, 2020 — Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval of Piqray® (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metast

Bavarian Nordic meddeler at Janssen har modtaget positiv anbefaling fra det Europæiske Lægemiddelagentur vedrørende godkendelse af ebolavaccinen29.5.2020 12:42:08 CESTpressemeddelelse

KØBENHAVN, Danmark, 29. maj 2020 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabets strategiske partner, Janssen Pharmaceutical Companies of Johnson & Johnson, har modtaget en positiv anbefaling fra udvalget for humanmedicinske lægemidler (CHMP) under det Europæiske Lægemiddelagentur (EMA) for vaccinen mod ebola, forårsaget af Zaire ebolavirussen. Der blev indsendt to ansøgninger med henblik på godkendelse af de to komponenter, der indgår i vaccinen; Ad26.ZEBOV, der er baseret på Janssen AdVac® teknologi, og MVA-BN® Filo, der er baseret på Bavarian Nordics MVA-BN® teknologi, og som gives ca. 8 uger efter den første dosis. Formålet med de to doser er at fremkalde langvarig immunitet mod ebolavirussen. Vaccinen er specifikt udformet til forebyggende vaccination i lande, der er i risiko for ebolaudbrud samt for andre risikogrupper, såsom sundhedsarbejdere, BSL4 laboratoriearbejdere, militærpersonale indsat fra andre lande, lufthavnspersonale og besøgende i højrisikolande. Jan

Bavarian Nordic Announces that Janssen has Received Positive CHMP Opinion for its Investigational Preventative Ebola Vaccine Regimen29.5.2020 12:42:08 CESTPress release

COPENHAGEN, Denmark, May 29, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its strategic partner Janssen Pharmaceutical Companies of Johnson & Johnson has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its investigational Ebola vaccine regimen for the prevention of the Ebola Virus Disease caused by the Zaire ebolavirus species. Two Marketing Authorisation Applications (MAAs) were submitted to the EMA in support of the vaccines in the two-dose regimen, which includes Ad26.ZEBOV as the first dose, based on Janssen’s proprietary AdVac® viral vector technology, and MVA-BN Filo as the second dose, based on Bavarian Nordic’s MVA-BN® technology, administered approximately eight weeks later. The goal of this two-dose approach is to induce long-term immunity against Ebola Virus Disease. The regimen is specifically designed to support preventative vaccination in countries that are at

CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer29.5.2020 12:03:00 CESTPress release

·Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to the brain, and could become Roche’s first tumour-agnostic therapy in Europe Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion under conditional marketing authorisation for Rozlytrek® (entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options. The CHMP has also recommended Rozlytrek for the treatment of adults with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with RO

RESULT OF RIKSBANK REVERSED AUCTION SEK BONDS MAY 29, 202029.5.2020 10:09:32 CESTPress release

Auction date2020-05-29Loan1061Coupon0.75 %ISIN-codeSE0011281922Maturity2029-11-12Tendered volume, SEK mln1,000 +/- 250Volume offered, SEK mln3,825Volume bought, SEK mln1,000Number of bids17Number of accepted bids2Average yield-0.040 %Lowest accepted yield-0.040 %Highest yield-0.039 %% accepted at lowest yield 90.00 Auction date 2020-05-29 Loan 1062 Coupon 0.125 % ISIN-code SE0013935319 Maturity 2031-05-12 Tendered volume, SEK mln 1,000 +/- 250 Volume offered, SEK mln 4,150 Volume bought, SEK mln 1,000 Number of bids 15 Number of accepted bids 4 Average yield 0.093 % Lowest accepted yield 0.089 % Highest yield 0.096 % % accepted at lowest yield 100.00